This House of Lords Library Briefing provides information on recent developments in connection with the availability of Pre-exposure Prophylaxis (PrEP) in England.Jump to full report >>
In 2019, the provision of Pre-exposure Prophylaxis (PrEP), an anti-HIV medication, has continued to attract attention. PrEP is a drug taken by HIV-negative individuals at risk of acquiring HIV, which reduces viral replication and minimises the chance of a permanent infection developing.
Although PrEP is widely available in Scotland, access in England has initially been through an impact trial. The Terrence Higgins Trust has campaigned for PrEP to be made available through routine commissioning in all parts of the country. It states that while it is “achievable” to “end HIV transmission in the UK”, this can only happen if “we use all of the tools available to us”, including PrEP. On 29 October 2019, the Secretary of State for Health and Social Care, Matt Hancock, said that the “roll-out from a trial to routine commissioning will happen in April (2020)”. However, various campaigners remain concerned that people will contract HIV while waiting to access the medication.
The key PrEP developments since 2016 have been:
The Department of Health and Social Care has stated that it will work with local authorities in England to plan for a “seamless transition” from the trial to routine commissioning in 2020/21.
Lords Library notes LLN-2019-0152
Author: Joe Skelton
The House of Lords Library delivers research and information services to Members and staff of the House in support of parliamentary business.